Verma et al. reported on the effects of the SGLT2 inhibitor empagliflozin (10 mg/day) 3 months after its initiation in terms of objective measurements of cardiac structure and function observed in 10 patients with T2DM and established cardiovascular disease. The gene discussed is SLC5A2; the disease is cardiovascular disorder.